



Bioanalytical & Biomarker Services

FOR IMMEDIATE RELEASE

August 2018

Contact: Media@kcasbio.com

**KCAS Bioanalytical and Biomarker Services
Welcomes Director of BioPharma**

Kansas City, KS. – (August) KCAS Bioanalytical and Biomarker Services, a laboratory services contract research organization (CRO) is pleased to announce the expansion of their team. Dr. Dawn Dufield, Ph.D., joins KCAS as Director of BioPharma.

Dr. Dawn Dufield was hired to launch an innovative large molecule LC-MS/MS group that will specialize in developing quantitative LC-MS/MS assays for biopharma molecules. Dr. Dufield was one of the early pioneers in using immunoaffinity combined with LC-MS/MS (also known as Hybrid LCMS) to offer increased selectivity and sensitivity when measuring biologics. She brings with her knowledge of protein LC-MS/MS utilizing meticulous sample preparation techniques, enzymatic digestions, and a strong background in all scales of chromatographic separations.

“We are absolutely thrilled to have Dr. Dufield join our team and lead our technical development service in protein analysis by mass spectrometry. Her outstanding credentials and expertise in this sector are well known and have positioned KCAS to continually evolve our ability to be the go-to outsourcing partner for the industry’s bioanalytical drug development needs.” stated John Bucksath, CEO.

Dr. Dufield will build and oversee KCAS’ Biopharma LC-MS/MS Department, maximize efficiencies through automation, initiate new technical platforms including high resolution mass spectrometry and develop complex assays to solve clients’ most challenging development issues. “My vision for KCAS is to become the premier bioanalytical lab providing superior support in the field of large molecule LC-MS/MS. Upon achieving this goal, KCAS will be recognized by the biopharma industry for leading expertise in quantitating an array of large molecule modalities for both biotherapeutic and biomarker assays using state-of-the-art instrumentation. KCAS will offer capabilities in several areas. One that I am particularly excited about is the ability to perform immunoaffinity LC-MS/MS or Hybrid LC-MS/MS on automated platforms at the protein or peptide level using Sciex 6500+ mass spectrometers coupled to micro, nano and multi-dimensional chromatography systems thus providing the ultimate sensitivity.” stated Dawn Dufield, Director of BioPharma.

Dr. Dufield joins KCAS from Pfizer where she worked for over 20 years developing qualitative and quantitative LC-MS/MS biotherapeutic and biomarker assays while helping to set PK/PD strategy. She also developed expertise in sample prep utilizing immunoaffinity multidimensional LC-MS/MS. She has numerous publications and presentations and has contributed to several recent white papers. Dr. Dufield earned her bachelor’s degree in Chemistry from Southwest Missouri State University in Springfield, MO and her Ph.D in BioAnalytical Chemistry from the University of Kansas in Lawrence, KS.

About KCAS

KCAS Bioanalytical & Biomarker Services is a contract laboratory with 39+ years of bioanalytical expertise. Centrally located in Kansas City, KCAS provides bioanalytical services for pharmaceutical and biopharmaceutical companies requiring PK, immunogenicity, and biomarker analysis operating a variety of equipment platforms to service a wide range of therapeutic areas. KCAS' team leverages a highly scientific staff with an average tenure in the field of bioanalysis/biomarker analysis of 22 years to provide clients of all sizes with expertise in robust assay development, validation, and sample analysis under Non-GLP, GLP, and GCP conditions for discovery, preclinical and clinical studies. Our teams have developed and validated more than 5,500 bioanalytical assays and have undergone 16 FDA inspections. Learn more at: www.kcasbio.com